|Home | About | Journals | Submit | Contact Us | Français|
Correspondence to: Naoyoshi Nagata, MD, Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. nnagata_ncgm/at/yahoo.co.jp
Telephone: +81-3-32027181 Fax: +81-3-32071038
Here, we report a case of fulminant gastrointestinal graft-versus-host disease (GI-GVHD) with cytomegalovirus (CMV) infection in 44-year-old woman. Despite the difficulties associated with the treatment of GI-GVHD and GI-CMV disease, the mucosal findings and the clinical course showed marked improvements during long-term clinical observation. The endoscopic findings were remarkable, with diffuse sloughing mucosa in the stomach and highly active inflammation and deep discrete ulcers throughout the colon. Changes in the CMV quantitative polymerase chain reaction results were correlated with the endoscopic mucosal findings and were useful for assessing the efficacy of the treatment. Although a definite diagnosis of GI-GVHD is generally made by endoscopy with biopsy, the gross appearance of this disease can vary depending on the endoscopy. In this paper, we also conduct a literature review of patients with GI-GVHD.
Graft-versus-host disease (GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (HSCT) and mainly attacks the skin, gastrointestinal (GI) tract and liver[1-5]. GI-GVHD, in particular, can cause life-threatening complications, such as massive diarrhea, hemorrhage, paralytic ileus, and perforation[6,7]; therefore, the accurate diagnosis of GI-GVHD is essential. Although endoscopic observation is an indispensable diagnostic tool, various mucosal patterns are observed on endoscopy. In addition, testing for cytomegalovirus (CMV) infection is necessary because the complication of GI-GVHD with CMV infection will reduce the quality of life (QoL) of the patients. This reduction in the QoL occurs because CMV-related GI disease is exacerbated by the administration of steroids for the treatment of GI-GVHD when antiviral drugs are not administered. Here, we report a rare case of fulminant GI-GVHD detected by endoscopy and its clinical course, and we review related literature on the endoscopic findings of GI-GVHD.
The patient, a 44-year-old woman with acute myeloid leukemia who was diagnosed 18 mo earlier, underwent allogeneic bone marrow transplantation 3 mo prior to the examination. A full-body skin rash appeared on day 26 after the transplantation. On day 85 after the transplantation, she experienced watery diarrhea more than 10 times per day and developed abdominal pain. Upper GI endoscopy showed diffuse sloughing of the mucosa with diffuse erythema and hemorrhage in the antrum and corpus of the stomach (Figure (Figure1A-D).1A-D). Lower GI endoscopy revealed multiple deep discrete ulcers with exudative and mucosal oozing in the terminal ileum end and throughout the entire colon (Figure (Figure1E1E and F). Biopsy specimens from the upper and lower GI tract revealed diffuse erythema, erosions, and sloughing mucosa with active bleeding in the stomach, as well as multiple erosions and a small discrete ulcer with active bleeding in the lower GI tract. Gland apoptosis showed histological evidence of acute GVHD (Figure (Figure2).2). Moreover, the biopsy specimens showed CMV infection detected by polymerase chain reaction (PCR) at remarkably elevated concentrations of 4.0 × 104 copies/μg DNA, but immunochemical staining for the CMV antibody was negative. Finally, the patient was diagnosed with severe GI-GVHD concomitant with a CMV infection. Other organ involvement included a whole-body skin rash and slight liver dysfunction.
The treatment for acute GVHD was started with an initial dose of prednisolone 1 mg/kg per day (50 mg/d) and for CMV infection with an initial dose of ganciclovir (GCV) 10 mg/kg per day. After 40 d of treatment, the patient improved clinically. Then, GCV was discontinued because of thrombocytopenia that appeared 60 d after the treatment. After 64 d, however, CMV was detected in the blood by a CMV-antigenemia assay, and the maintenance dose of GCV (5 mg/kg per day) was resumed. After 70 d, upper and lower endoscopy showed that the endoscopic findings of mucosal sloughing had improved (Figure (Figure3A-D)3A-D) but that the colonic mucosa remained ulcerative and inflamed (Figure (Figure3E3E and F). Both upper and lower GI tract biopsies revealed CMV-infected cells in immunohistochemically stained tissue specimens (Figure (Figure4),4), and the CMV-PCR from the GI tract biopsy was 2.0 × 105 copies/μg DNA. Intravenous GCV at 5 mg/kg every 12 h as the induction therapy was re-started and then changed to the maintenance therapy, and the prednisolone dose was tapered. Although the treatment continued for an additional 102 d, the CMV-PCR from the GI tract biopsy was 1.0 × 103 copies/μg DNA. Oral valganciclovir at 900 mg/d was started, with oral prednisolone 10 mg administered every other day. After 162 d, the upper and lower endoscopy showed notable improvements in the mucosal findings (Figure (Figure5),5), and the CMV-PCR count from a GI tract biopsy was within the normal range of < 4.0 × 10 copies/μg DNA.
Nausea and vomiting, appetite loss, abdominal pain, and watery diarrhea are common symptoms of GI-GVHD. Watery diarrhea appears in almost all cases of GI-GVHD and occasionally becomes chronic or causes bleeding. Therefore, this symptom is a major factor that reduces patient QoL. Moreover, after HSCT, CMV infection of the GI mucosa and GI-GVHD can both cause diarrhea[12,13].
Diseases characterized by the development of GI symptoms after HSCT include not only CMV and GI-GVHD infection but also virus infections caused by enterovirus, adenovirus, rotavirus, and Epstein-Barr virus, complications with bacterial and fungus infections, and colitis associated with thrombotic microangiopathy and regimen-related toxicity. In routine clinical examination, differentiating among these diseases is difficult, particularly because GI-GVHD is frequently associated with CMV infection[15,16]. In this case, because of the severe GI-GVHD accompanied by CMV infection, the patient developed frequent and long-term bloody diarrhea and abdominal pain, which appeared to have led to serious symptoms such as anemia, malnutrition, and dehydration.
The endoscopic findings reflected the severity of the clinical symptoms. The lower GI tract exhibited severe signs of multiple deep ulcers, edema, and erythema, with no normal mucosa observed. The upper GI endoscopy revealed diffuse sloughing of the mucosa in the stomach, except for the antrum. Although the endoscopic findings of chronic GI-GVHD may include the characteristic esophageal web and strictures, various endoscopic findings are associated with acute GI-GVHD depending on the severity of the inflammation. We reviewed the English literature in the MEDLINE database by searching with “gastrointestinal”, “GVHD”, and “endoscopy” as key words (Table (Table1).1). Although there are some reports of normal mucosal findings, a large number of studies reported findings of erythema, erosions, and edema. Because the symptoms were generally mild in the upper GI tract, the lower GI tract often had relatively severe inflammatory symptoms, with occasional actively bleeding ulcers. In addition, although tortoise shell-like mucosa and pseudomembrane formation are occasionally observed, no particular findings are reportedly associated with the colorectal mucosa. Moreover, even though some papers report mucosal sloughing and ulceration, a wide area of sloughing mucosa along with ulcers and inflamed mucosa, as observed in the present case, has never been reported. We believe that a combination of severe GVHD and CMV infection is the pathogenesis responsible for these symptoms. According to He et al, GI-GVHD accompanied by CMV infection causes deep, discrete ulcers. The ischemic consequences of occluded blood vessels caused by enlarged vascular endothelial cells due to CMV infection are thought to be the mechanism underlying the GI mucosal damage. Similarly, ischemic alteration, in addition to the cytotoxicity caused by GVHD, is a likely cause of the severe symptoms in our patient.
The early and accurate diagnosis of CMV infection in the GI tract is the key to preventing severe symptoms, such as perforation and bleeding. In this case, even though immunostaining with an anti-CMV antibody was negative, the quantitative PCR results of the biopsy specimens were positive, with a high value of 1.0 × 104 copies/μg DNA, which enabled the diagnosis of CMV-GID. The diagnostic accuracy of the quantitative PCR method using biopsy samples is reportedly superior to that of immunostaining to determine the involvement of CMV in the GI symptoms. This case showed that the results of the CMV quantitative PCR were closely correlated with the post-treatment improvement of the mucosa, suggesting the usefulness of the technique for evaluating the effects of CMV treatment.
In conclusion, when endoscopic observation is performed on HSCT patients with postoperative GI symptoms, it is necessary to look for signs of mucosal sloughing and ulcers. In addition to a detailed endoscopic observation, biopsy samples should be examined for the characteristic pathological features of GVHD and for signs of CMV infection. The course of this case suggests that the quantitative PCR of biopsy samples is useful for revealing CMV infection in the GI tract.
We thank Hisae Kawashiro, the clinical research coordinator, for helping with the data collection.
Supported by Grant from the National Center for Global Health and Medicine
P- Reviewers Kiyan M, Yilmaz M S- Editor Gou SX L- Editor A E- Editor Xiong L